Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer

• Published in: Journal for immunotherapy of cancer Vol. 8; no. 1; p. e000110
• Main Authors: Sun, Jie, Zhang, Zicheng, Bao, Siqi, Yan, Congcong, Hou, Ping, Wu, Nan, Su, Jianzhong, Xu, Liangde, Zhou, Meng
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.02.2020; BMJ Publishing Group
• Subjects: Biomarkers; Biomedical engineering; Cancer; Clinical outcomes; Datasets; Gene expression; Genomes; Immunotherapy; Immunotherapy Biomarkers; Lung cancer; Medical prognosis; Melanoma; Patients; Regression analysis; China; computational psychiatry; medicine; molecular immunogene; oncology
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2019-000110

BackgroundIncreasing evidence has demonstrated the functional relevance of long non-coding RNAs (lncRNAs) to immunity regulation and the tumor microenvironment in non-small cell lung cancer (NSCLC). However, tumor immune infiltration-associated lncRNAs and their value in improving clinical outcomes and immunotherapy remain largely unexplored.MethodsWe developed a computational approach to identify an lncRNA signature (TILSig) as an indicator of immune cell infiltration in patients with NSCLC through integrative analysis for lncRNA, immune and clinical profiles of 115 immune cell lines, 187 NSCLC cell lines and 1533 patients with NSCLC. Then the influence of the TILSig on the prognosis and immunotherapy in NSCLC was comprehensively investigated.ResultsComputational immune and lncRNA profiling analysis identified an lncRNA signature (TILSig) consisting of seven lncRNAs associated with tumor immune infiltration. The TILSig significantly stratified patients into the immune-cold group and immune-hot group in both training and validation cohorts. These immune-hot patients exhibit significantly improved survival outcome and greater immune cell infiltration compared with immune-cold patients. Multivariate analysis revealed that the TILSig is an independent predictive factor after adjusting for other clinical factors. Further analysis accounting for TILSig and immune checkpoint gene revealed that the TILSig has a discriminatory power in patients with similar expression levels of immune checkpoint genes and significantly prolonged survival was observed for patients with low TILSig and low immune checkpoint gene expression implying a better response to immune checkpoint inhibitor (ICI) immunotherapy.ConclusionsOur finding demonstrated the importance and value of lncRNAs in evaluating the immune infiltrate of the tumor and highlighted the potential of lncRNA coupled with specific immune checkpoint factors as predictive biomarkers of ICI response to enable a more precise selection of patients.